(Z)-3-[1-(3-Chlorophenyl)-1-(4-methanesulfonylphenyl)methylidene]dihydrofuran-2-one | 197438-48-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-3-[1-(3-Chlorophenyl)-1-(4-methanesulfonylphenyl)methylidene]dihydrofuran-2-one
• 英文别名: 3-[(3-chloro-phenyl)-(4-methanesulfonyl-phenyt)-methylene]-dihydro-furan-2-one；3-((3-Chlorophenyl)(4-(methylsulfonyl)phenyl)methylene)dihydro-2(3H)-furanone, (3Z)-；(3Z)-3-[(3-chlorophenyl)-(4-methylsulfonylphenyl)methylidene]oxolan-2-one
• CAS: 197438-48-5
• 化学式: C₁₈H₁₅ClO₄S
• 分子量: 362.834
• InChiKey: SWQSXNPJMCRJFV-MSUUIHNZSA-N

物化性质

• 沸点：
  616.2±55.0 °C(Predicted)
• 密度：
  1.373±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-5,5-Dimethyl-3-[1-(4-fluorophenyl)-1-(4-methanesulfonylphenyl)methylidene]dihydrofuran-2-one 、 (Z)-3-[1-(3-Chlorophenyl)-1-(4-methanesulfonylphenyl)methylidene]dihydrofuran-2-one 生成 5-Ethyl-3-[1-(4-fluorophenyl)-1-(4-methylthiophenyl)methylidene]dihydrofuran-2-one
  参考文献：
  名称：

  Diarylmethylidenefuran derivatives and their uses in therapeutics

  摘要：

  本发明涉及公式 ##STR1## 的衍生物及其在治疗中的应用，特别是作为具有抗炎和镇痛性质的药物。

  公开号：

  US05807873A1

文献信息

• 4-Phenylamino-quinazolin-6-yl-amides
  申请人：Fakhoury Alan Stephen

  公开号：US20050250761A1

  公开（公告）日：2005-11-10

  This invention provides quinazoline compounds of the formula: wherein: R 1 is halo; R 2 is H or halo; R 3 is a) C 1 -C 3 alkyl, optionally substituted by halo; or b) —(CH 2 ) n -morpholino, —(CH 2 ) n -piperidine, —(CH 2 ) n -piperazine, —(CH 2 ) n —-piperazine-N(C 1 -C 3 alkyl), —(CH 2 ) n -pyrrolidine, or —(CH 2 ) n -imidazole; n is 1 to 4; R 4 is —(CH 2 ) m -Het; Het is morpholine, piperidine, piperazine, piperazine-N(C 1 -C 3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH 2 , NH(C 1 -C 3 alkyl) or N (C 1 -C 3 alkyl) 2 ; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

  这项发明提供了式子为的喹唑啉化合物：其中：R1是卤素；R2是H或卤素；R3是a）C1-C3烷基，可选择地被卤素取代；或b）—（CH2）n-吗啉基、—（CH2）n-哌啶基、—（CH2）n-哌嗪基、—（CH2）n-哌嗪-N（C1-C3烷基）、—（CH2）n-吡咯烷基或—（CH2）n-咪唑基；n为1至4；R4是—（CH2）m-Het；Het是吗啉、哌啶、哌嗪、哌嗪-N（C1-C3烷基）、咪唑、吡咯烷、环庚烷、3,4-二氢-2H-吡啶或3,6-二氢-2H-吡啶，每个可选择地被烷基、卤素、OH、NH2、NH（C1-C3烷基）或N（C1-C3烷基）2取代；m为1-3；X为O、S或NH；或其药学上可接受的盐，以及用于制备它们的过程和中间化合物，有用的药用组合物和使用这些化合物治疗增生性疾病的方法。
• [EN] 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES<br/>[FR] 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES
  申请人：WARNER LAMBERT CO

  公开号：WO2005107758A1

  公开（公告）日：2005-11-17

  The invention provides quinazoline compounds of the formula: wherein R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) -(CH2)n-morpholino, -(CH2)n-piperidine, -(CH2)n-piperazine, -(CH2)n-piperazine-N(C1-C3 alkyl), -(CH2)n-pyrrolidine, or -(CH2)n imidazole; n is 1 to 4; R4 is -(CH2)m-Het; Het is morpholine,piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole,pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N (C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.

  该发明提供了式子为：其中R1为卤素; R2为H或卤素; R3为a) C1-C3烷基，可选地被卤素取代; 或b) -(CH2)n-吗啡啶基、-(CH2)n-哌啶基、-(CH2)n-哌嗪基、-(CH2)n-哌嗪-N(C1-C3烷基)、-(CH2)n-吡咯烷基或-(CH2)n-咪唑基; n为1至4; R4为-(CH2)m-Het; Het为吗啡啶、哌啶、哌嗪、哌嗪-N(C1-C3烷基)、咪唑、吡咯烷基、氮杂七环、3,4-二氢-2H-吡啶或3,6-二氢-2H-吡啶，每个可选地被烷基、卤素、OH、NH2、NH(C1-C3烷基)或N (C1-C3烷基)2取代; m为1-3; X为O、S或NH; 或其药学上可接受的盐，以及制备它们的过程和中间化合物，有用的制药组合物和使用这些化合物治疗增生性疾病的方法。
• BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Morris Joel

  公开号：US20090111805A1

  公开（公告）日：2009-04-30

  The invention relates to compounds of the formula I: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, V, W, R 4 , R 5 , R 6 , R 7 , and ring B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I and to pharmaceutical compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of preparing the compounds of formula I.

  本发明涉及化合物I的公式，以及其药学上可接受的盐和溶剂化物，其中X、Z、V、W、R4、R5、R6、R7和环B的定义如本文所述。本发明还涉及通过给予公式I化合物治疗哺乳动物的异常细胞生长的方法，以及含有公式I化合物的用于治疗此类疾病的药物组合物。本发明还涉及制备公式I化合物的方法。
• HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Bhattacharya Samit Kumar

  公开号：US20090281073A1

  公开（公告）日：2009-11-12

  This invention relates to compounds of Formula (I), and to pharmaceutically acceptable salts and solvates thereof, wherein Z, W, X, Y, V, R 1 , R 2 , and R 3 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of Formula (I) and to pharmaceutical compositions for treating such disorders which contain the compounds of Formula (I). The invention also relates to methods of preparing the compounds of Formula (I).

  本发明涉及公式(I)的化合物，以及其药学上可接受的盐和溶剂化物，其中Z，W，X，Y，V，R1，R2和R3的定义如本文所述。该发明还涉及通过给予公式(I)的化合物来治疗哺乳动物中的异常细胞生长的方法，以及含有公式(I)的化合物用于治疗这种疾病的药物组合物。该发明还涉及制备公式(I)的化合物的方法。
• NANOPARTICLES COMPRISING IONIZABLE, POORLY WATER SOLUBLE CELLULOSIC POLYMERS
  申请人：Bloom Corey Jay

  公开号：US20100215747A1

  公开（公告）日：2010-08-26

  A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.

  一种药物组合物包括含有可离子化、难溶于水的纤维素聚合物的纳米粒子。